InMed Pharmaceuticals Inc. (TSE:IN – Get Free Report) shares traded down 1.6% during mid-day trading on Monday . The company traded as low as C$4.13 and last traded at C$4.19. 17,035 shares traded hands during mid-day trading, a decline of 42% from the average session volume of 29,552 shares. The stock had previously closed at C$4.26.
InMed Pharmaceuticals Stock Performance
The firm has a 50-day moving average price of C$4.19. The company has a quick ratio of 1.45, a current ratio of 2.13 and a debt-to-equity ratio of 8.48. The firm has a market capitalization of C$33.73 million and a PE ratio of -2.77.
About InMed Pharmaceuticals
InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain.
Read More
- Five stocks we like better than InMed Pharmaceuticals
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Semtech Stock Climbs as AI Boom Drives Turnaround Success
- What is a support level?
- 3 Companies Leading the Way With Aggressive Stock Buybacks
- The How and Why of Investing in Gold Stocks
- Is It Time to Buy Nuclear Energy Stocks After the Latest Dip?
Receive News & Ratings for InMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
